E

Evofem Biosciences Inc
F:1AQ1

Watchlist Manager
Evofem Biosciences Inc
F:1AQ1
Watchlist
Price: 0.1432 EUR -2.59% Market Closed
Market Cap: €65.8m

Relative Value

1AQ1 price has not been updated for more than 8 months. This may indicate that the stock has been delisted.
1AQ1 doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of 1AQ1.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

1AQ1 Relative Value
Base Case
Not Available
E
Worst Case
Base Case
Best Case

Multiples Across Competitors

1AQ1 Competitors Multiples
Evofem Biosciences Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Evofem Biosciences Inc
F:1AQ1
65.8m EUR 4.8 1.6 -5.4 -5.3
US
Eli Lilly and Co
NYSE:LLY
972.2B USD 16.3 52.8 35.4 38
US
Johnson & Johnson
NYSE:JNJ
547.5B USD 5.8 20.4 14.3 17.5
CH
Roche Holding AG
SIX:ROG
277.1B CHF 4.4 29 12.4 14.4
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP 4.9 30.2 19.7 28.8
CH
Novartis AG
SIX:NOVN
219B CHF 5 19.3 15.5 20
US
Merck & Co Inc
NYSE:MRK
272.1B USD 4.2 14.3 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.2 15.9 11.1 12.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
148.3B USD 2.4 15.1 7.6 10.4
FR
Sanofi SA
PAR:SAN
93.8B EUR 1.4 6.8 6.2 6.2
P/E Multiple
Earnings Growth PEG
US
E
Evofem Biosciences Inc
F:1AQ1
Average P/E: 20.5
1.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.8
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.4
6%
3.4
CH
Roche Holding AG
SIX:ROG
29
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
19.3
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.3
14%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.9
2%
7.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
27%
0.6
FR
Sanofi SA
PAR:SAN
6.8
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
E
Evofem Biosciences Inc
F:1AQ1
Average EV/EBITDA: 47.7
Negative Multiple: -5.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.4
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.3
2%
7.1
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
CH
Novartis AG
SIX:NOVN
15.5
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
6.2
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
E
Evofem Biosciences Inc
F:1AQ1
Average EV/EBIT: 102.5
Negative Multiple: -5.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.5
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.4
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.8
23%
1.3
CH
Novartis AG
SIX:NOVN
20
12%
1.7
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5
FR
Sanofi SA
PAR:SAN
6.2
15%
0.4